2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
03/06/19MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the Cowen & Co. 39th Annual Health Care Conference on Wednesday, March 13th, 2019, at 10:40 a.m. ET in Boston, MA. A webcast of the presentation will be available by visiting the Investor... 
03/04/19MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
Mavacamten Well Tolerated; Results Show Statistically Significant Elimination of Obstruction and Durable NYHA Class Improvements Statistically Significant Improvement in Several Key Biomarkers Suggest Potential for Mavacamten to Slow or Reverse Disease Progression Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT); Data Presentation at American College of Cardiology on Sunday, March 17, 2019 SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYO... 
02/28/19MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results
Company to Host Conference Call and Webcast on March 4, 2019 at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018.  “2018 was MyoKardia’s most significant year of progress towards building ... 
01/23/19MyoKardia Appoints William Fairey as Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial Officer and Executive Vice President.  Mr. Fairey will have global responsibility for oversight of all aspects of commercial operations and serve as a key member of MyoKardia’s executive lea... 
01/03/19MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th, 2019, at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco. A webcast of the presentation will be available by visiting the Invest... 
01/02/19MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
Management to Host Conference Call at 8:30 a.m. ET/5:30 a.m. PT SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not be extended beyond the initial research term, which ended on...